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preceding viral illness [2,3]. Leucopenia has also been a ﬁnding
in cases during the current pandemic of inﬂuenza A (H1N1)
infection [8–10]. Our patient had leucopenia with mild neutro-
penia and lymphopenia.
The disease is self-limiting and, when the myositis devel-
ops, the patient is already at the early convalescent phase of
the viral illness. Therefore, antivirals are not usually indi-
cated. Only supportive treatment and follow-up aiming to
monitor full recovery of the patient are required [17]. In our
case, the patient was already afebrile at the time of admis-
sion and he recovered fully in less than 48 h.
BACM is an acute, self-limiting condition with an excellent
prognosis, which occurs during the acute convalescent phase
of viral illnesses, mainly inﬂuenza A and inﬂuenza B infec-
tions, and requires no therapeutic intervention. Correct diag-
nosis by considering the characteristic clinical and laboratory
ﬁndings as well as the history of the preceding viral illness
can prevent unnecessary diagnostic procedures and reassure
both the parents and the patient of the excellent prognosis.
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Abstract
We report two occurrences of spontaneous pneumomediasti-
num (SPM) complicating pneumonia in Japanese children infected
with the novel inﬂuenza A (H1N1) virus (IV). General practitio-
ners especially should suspect possible SPM when examining and
treating children with the novel inﬂuenza accompanied by status
asthmaticus or wheezing. The presented patients illustrate the
speciﬁc clinical and radiological signs associated with SPM
complicating pneumonia in children infected with A(HINI)v.
Keywords: A (H1N1) virus, children, inﬂuenza, pneumonia,
spontaneous pneumomediastinum
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A novel inﬂuenza A (H1N1) virus (IV), was identiﬁed as the
cause of outbreaks of febrile respiratory infection ranging
from self-limiting to severe illness in Mexico, the USA,
Canada, and elsewhere in the spring of 2009 [1]. Triple-
reassortant IV containing genes from avian, human and swine
inﬂuenza viruses emerged and became enzootic among swine
herds in North America during the late 1990s [2]. Clinical
aspects of the ﬁrst 11 patients sporadically infected with IV
were reported to the CDC in the USA, from December
2005 to February 2009 [2]. Accordingly, surveillance was
implemented for human infections with inﬂuenza A viruses
that could not be subtyped. Specimens were sent to the
CDC RT-PCR conﬁrmatory testing for IV. A total of 642
conﬁrmed cases of IV infection were identiﬁed from 15 April
to 5 May. Sixty percent of patients were aged 18 years or
younger, indicating that children may be particularly suscepti-
ble to IV [1].
Eighteen cases of pneumonia and conﬁrmed IV infection
were identiﬁed among 98 patients hospitalized for acute
respiratory illness from 24 March to 24 April in Mexico,
including ﬁve patients aged 15 years or younger [3]. All
patients had fever, cough, dyspnoea, increased serum lactate
dehydrogenase levels, and bilateral patchy pulmonary shad-
ows on roentgenograms. Other common ﬁndings were
increased creatine kinase levels and lymphopaenia. Mechani-
cal ventilation was required for 12 patients, and seven
patients died.
We report two IV-infected Japanese children with sponta-
neous pneumomediastinum (SPM) complicating pneumonia.
IV was conﬁrmed in nasopharyngeal-swab specimens using
real-time RT-PCR as previously described [4–6]. IV-speciﬁc
primers for ampliﬁcation (87 bp) of the nonstructural protein
1 gene (accession number FJ966086) included a sense
primer, 5¢- GCGAACTTCAGTGTAATC-3¢, and a reverse
primer, 5¢- AATTTCTCCAACTATTGCTC-3¢; the speciﬁc
molecular beacon probe used was 6-carboxyﬂuorescein-
CGCGATGACCTTGATACTACTAAGGGCTTATCGCG-
black hole quencher 1. IV-associated pneumonia was based
on evidence of both inﬂuenza-like illnesses with opacities on
chest radiographs and laboratory-conﬁrmed IV infection [3].
Case 1
A previously healthy 6-year-old girl with a 2-day history of
cough was referred because of fever and dyspnoea. Respira-
tory distress was evident from tachypnoea (respiratory rate,
48/min) and supraclavicular and intercostal inspiratory retrac-
tion (Table 1). Bilateral expiratory rhonchi were apparent on
auscultation, together with insufﬁcient vesicular sounds. The
patient required oxygen supplementation (5 L/min) because
percutaneous oxygen saturation (SpO2) was 84% when
breathing room air. A chest roentgenogram on admission
indicated air leakage into the mediastinum, together with
bilateral hyperaeration and a right middle-lobe inﬁltrate
(Fig. 1). She was treated with continuous inhalation of a
bronchodilator and intravenous prednisolone (10–30 mg
daily for 4 days), as well as antiviral therapy. On day 3 after
admission, the radiographic SPM ﬁndings had resolved.
Case 2
An 8-year-old boy with a past history of allergic rhinitis had
fever and cough for 1 day, and presented with chest pain
and dyspnoea. Tachypnoea (36/min) was accompanied by
supraclavicular and intercostal inspiratory retraction
(Table 1). Vesicular sounds were insufﬁcient over the left
hemithorax, with neither rhonchi nor rales. The patient
required oxygen supplementation (3 L/min) because SpO2
was 91% when breathing room air. Chest roentgenography
on admission indicated air leakage into the mediastinum and
neck, as well as bilateral hyperaeration and a left lower lobe
inﬁltrate (Fig. 1). The patient was treated with continuous
inhalation of a bronchodilator and intravenous administration
of both aminophylline (0.6 mg/kg/h for 7 days) and predniso-
lone (10–30 mg daily for 3 days), together with antiviral
therapy. On day 4 after admission, there was no evidence
of SPM.
Nineteen IV-infected children with pneumonia (n = 16) or
bronchitis (n = 3) were admitted to our department from 9
August to 25 September. Clinical and laboratory features,
treatment, and outcomes are shown in Table 1. The two
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patients with SPM represented 10.5%. To the best of our
knowledge, this is the ﬁrst report of SPM complicating
pneumonia in IV-infected children.
A rare disorder, SPM typically is triggered by respiratory
infection and inﬂammation. It follows intrathoracic pressure
increases leading to rupture of alveoli or pneumatoceles near
the mediastinal pleura with air leakage along vessels. Addi-
tionally, SPM can complicate pulmonary emphysema, with air
drainage through the interstitium to the hilum, mediastinum,
neck, and skin [7].
Pneumonias complicated by SPM most notably include
Pneumocystis jirovecii pneumonia (PCP) [8]. High-resolution
chest computed tomography in a PCP patient was reported
to show SPM associated with peripheral air-trapping in the
right middle lobe [8]. Two patients presenting with tension
SPM, which is often fatal, both had AIDS-related PCP [9].
SPM subsequent to seasonal inﬂuenza is relatively rare, even
though a patient with inﬂuenza virus bronchiolitis compli-
cated by SPM has been described [10]. Our observations
suggest a possible high prevalence of SPM in IV-infected
children that may reﬂect a characteristic pathology in the
respiratory tract.
In children, SPM is observed most commonly in status asth-
maticus, bronchiolitis or bronchitis with casts [11,12], but it
may also occur in any patient during a Valsalva manoeuver
related to coughing, forceful vomiting or wheezing [13]. Inter-
estingly, SPM has occurred in status asthmaticus associated
with inﬂuenza [14]. Clinicians, therefore, should consider the
possibility of SPM when examining and treating children with
both novel inﬂuenza and wheezing or status asthmaticus.
D F
B
D F
E
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FIG. 1. Chest roentgenograms showing spontaneous pneumomediastinum (arrows) complicating pneumonia in two children (case 1, upper row;
case 2, lower row) infected with inﬂuenza A (H1N1) virus. The left images are frontal (posterior-anterior) views, and the right images are lateral
views. Arrowheads indicate pulmonary inﬁltrates in each patient. A, spinnaker sail sign (angel wing sign); B, continuous diaphragm sign; C, verti-
cal lucent streak on the left side of the heart; D, subcutaneous emphysema; E, retrosternal emphysema; F, posterior superior mediastinal
emphysema.
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In summary, SPM in children generally resolves spontane-
ously with aggressive supportive care. Our patients illustrate
the speciﬁc clinical and radiologic signs associated with SPM
complicating pneumonia in IV-infected children. Surveillance
results concerning paediatric deaths (n = 36) associated with
the 2009 pandemic IV infection have been reported for April
to August in the USA [15]. Clinicians should also be aware
that an early diagnosis of inﬂuenza can allow for prompt initi-
ation of antiviral therapy for children with an increased risk
of severe illness.
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